Catalyst Event

Jiangsu Hengrui Pharmaceuticals Co Ltd (1276) · Other

From Akros SCHK HK-Global Genomics Index (ASHGGENM)

4/28/2026, 12:00:00 AM

OtherSentiment: Positive

Subsidiary clinical trial approval for SHR-2173 (myasthenia gravis) on April 28, 2026; low importance reflects expected >1% price impact. scheduled

Korean Translation

2026년 4월 28일 자회사의 SHR-2173 주사제(중증 근무력증) NMPA 임상시험 승인 발표 예정. 1% 이상의 주가 영향이 예상됨

Related Recent Events

View Full Timeline